To date, adalimumab (ADA) is the only biotechnology drug approved for the management of
hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became …

Introduction Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high
unmet need for effective medical management. Clinically, it is characterized by inflammatory …

This is the second European Crohn's and Colitis Organisation [ECCO] evidence-based
consensus on extraintestinal manifestations [EIMs] of inflammatory bowel disease [IBD] and …

Introduction Hidradenitis suppurativa (HS) is a frequently debilitating, inflammatory skin
condition. Patients may have a limited response to adalimumab, currently the only Food and …

Introduction This second part of the S2k guidelines is an update of the 2015 S1 European
guidelines. Objective These guidelines aim to provide an accepted decision aid for the …

Hidradenitis suppurativa (HS) is a chronic, relapsing, and debilitating inflammatory skin
disease with a profound impact on health-related quality of life. 1, 2 The disease burden of …

Hidradenitis suppurativa (HS) as a paradoxical adverse event (PAE) from using anti-
interleukin (IL)-1 has not been reported in the literature, to our knowledge. We herein report …

Hidradenitis suppurativa (HS) is a chronic, oftentimes, debilitating inflammatory skin
condition characterized by painful recurrent abscesses, inflammatory nodules, and tunnels …

With advances in drug development and our understanding of the pathophysiology of skin
disease, biologic medications have emerged as powerful management tools for …

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that presents as
painful, deep-seated nodules, sinus tracts, and abscesses in about 1% of the population …